Partnering strategy

We offer licensing and partnering opportunities:

A worldwide license for Memogain® (AD candidate nominated  in March 2008), which is protected under international patents filed in 2005 and 2008 (use and composition of matter) and international trademark. (read more)

License opportunities for lead molecules in non-AD indications.

Collaboration on nicotinic receptor pharmacology, including access to cell lines, antibodies, and services.

Collaborations to optimize CNS active lead molecules for brain access, increasing their therapeutic window and potency.